News

Michael French, president and CEO of MDRNA, said: “While our focus remains the development of RNAi-based therapeutics, we believe that the intranasal assets from our predecessor company, Nastech

The analysis indicates that patients with KRAS wild-type tumors bearing a BRAF mutation also benefit from Erbitux treatment; therefore, KRAS remains the only validated, clinically predictive marker of

The seal-inspection tool forms part of the PowerChek and PowerChek Plus x-ray inspection systems. These multi-tasking inspection tools are the technological defenders of brand values. They catch several

SOCMA has reported that, in the notice, EPA identified classes of facilities within the industry ‘for which the agency plans to develop, as necessary, a proposed regulation identifying

The company said that the facility supports several recently announced partnerships, including one with Roche and Genentech, a wholly-owned member of the Roche Group, to develop and commercialise

The BVA-100 enables measurement of whole blood volume, including plasma volume and red blood cell volume. It also permits measurement of the rate of transudation of albumin across

Ampyra has demonstrated efficacy in people with all four major types of MS (relapsing remitting, secondary progressive, progressive relapsing and primary progressive). Ampyra can be used alone or

ACTB1003 is a novel oral kinase inhibitor that targets cancer cells through multiple modes of action. ACTB1003 inhibits cancer cell growth by targeting the FGF receptor family, which

Biocon is in talks with BiotecCorp to manufacture Biopharmaceutical products and formulation, within Malaysia’s Nusajaya, Iskandar Malaysia, known as Bio-XCell Ecosystem. Biocon is also developing biotechnology infrastructure in